论文部分内容阅读
Colorectal cancer (CRC) is a leading cause of cancer death, and primary prevention remains the best approach to reduce overall morbidity and mortality of CRC.Cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) promotes CRC progression, and both nonselective cyclooxygenase inhibitors (NSAIDs) and selective COX-2 inhibitors reduce the number and size of colonic adenomas.